All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALN-HSD
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALN-HSD
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Company has submitted a clinical trial authorization application to The Medicines and Healthcare Products Regulatory Agency in the U.K to initiate a Phase 1 study of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 for the treatment of NASH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LPCN 1148
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
The Phase 2 proof-of-concept study will evaluate the therapeutic potential of LPCN 1148, for the treatment of liver cirrhosis in adult male cirrhotic patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TLY012
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Funding January 30, 2020
Details:
Theraly Fibrosis has been awarded a Small Business Innovation Research Phase II grant by the National Institutes of Health to support development of TLY012 for treatment of chronic pancreatitis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
